Research ArticleClinical (Oncology: GU)
Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Benedikt Feuerecker, Maythinee Chantadisai, Anne Allmann, Robert Tauber, Jakob Allmann, Lisa Steinhelfer, Isabel Rauscher, Alexander Wurzer, Hans-Jürgen Wester, Wolfgang A. Weber, Calogero d’Alessandria and Matthias Eiber
Journal of Nuclear Medicine June 2022, 63 (6) 833-839; DOI: https://doi.org/10.2967/jnumed.121.262671
Benedikt Feuerecker
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
2Partnersite München, German Cancer Consortium (DKTK), Heidelberg, Germany;
3Department of Radiology, School of Medicine, Technical University of Munich, München, Germany;
Maythinee Chantadisai
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
Anne Allmann
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
Robert Tauber
4Department of Urology, School of Medicine, Technical University of Munich, München, Germany; and
Jakob Allmann
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
Lisa Steinhelfer
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
Isabel Rauscher
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
Alexander Wurzer
5Department of Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany
Hans-Jürgen Wester
5Department of Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany
Wolfgang A. Weber
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
2Partnersite München, German Cancer Consortium (DKTK), Heidelberg, Germany;
Calogero d’Alessandria
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
Matthias Eiber
1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, München, Germany;
2Partnersite München, German Cancer Consortium (DKTK), Heidelberg, Germany;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 6
June 1, 2022
Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Benedikt Feuerecker, Maythinee Chantadisai, Anne Allmann, Robert Tauber, Jakob Allmann, Lisa Steinhelfer, Isabel Rauscher, Alexander Wurzer, Hans-Jürgen Wester, Wolfgang A. Weber, Calogero d’Alessandria, Matthias Eiber
Journal of Nuclear Medicine Jun 2022, 63 (6) 833-839; DOI: 10.2967/jnumed.121.262671
Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Benedikt Feuerecker, Maythinee Chantadisai, Anne Allmann, Robert Tauber, Jakob Allmann, Lisa Steinhelfer, Isabel Rauscher, Alexander Wurzer, Hans-Jürgen Wester, Wolfgang A. Weber, Calogero d’Alessandria, Matthias Eiber
Journal of Nuclear Medicine Jun 2022, 63 (6) 833-839; DOI: 10.2967/jnumed.121.262671
Jump to section
Related Articles
Cited By...
- An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
- Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
- Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
- Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer